Sandoz Group AG | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129132	Press releases

Home
Companies
Sandoz Group AG

PRESS RELEASE

published on 03/18/2026 at 08:30, 5 months 24 days ago

Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
Sandoz partners with Samsung Bioepis on up to five biosimilars, expanding its pipeline to 32 assets. The agreement aims to broaden patient access to high-quality medicines worldwide

Partnership Biosimilars Pipeline Sandoz Samsung Bioepis
BRIEF

published on 03/11/2026 at 07:05, 6 months ago

Sandoz renforce sa situation financière grâce à une émission d'obligations de 550 millions de francs suisses et à une extension de crédit.

Stratégie Financière Facilité De Crédit Qualité D'investissement Refinancement De La Dette Obligations Sandoz
BRIEF

published on 03/11/2026 at 07:05, 6 months ago

Sandoz to Strengthen Financial Position with CHF 550 Million Bonds and Credit Extension

Credit Facility Financial Strategy Investment Grade Debt Refinancing Sandoz Bonds
PRESS RELEASE

published on 03/11/2026 at 07:00, 6 months ago

Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year
Sandoz Group AG issues CHF 550 million in bonds & extends USD 2 billion revolving credit facility. Bonds for refinancing & general corporate purposes. Extension strengthens balance sheet

Credit Facility Refinancing Corporate Purposes Bonds Sandoz
BRIEF

published on 03/10/2026 at 07:05, 6 months 1 day ago

Sandoz crée une nouvelle unité de biosimilaires et nomme Armin Metzger à sa tête.

Direction Croissance Stratégique Biosimilaires Génériques Sandoz
BRIEF

published on 03/10/2026 at 07:05, 6 months 1 day ago

Sandoz Establishes New Biosimilar Unit, Appoints Armin Metzger

Biosimilars Strategic Growth Leadership Generics Sandoz
PRESS RELEASE

published on 03/10/2026 at 07:00, 6 months 1 day ago

Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Sandoz creates new global biosimilar development, manufacturing, and supply unit with appointment of industry veteran Armin Metzger to lead growth strategy

Manufacturing Development Biosimilar Sandoz Armin Metzger
BRIEF

published on 02/25/2026 at 07:05, 6 months 14 days ago

Sandoz annonce de solides résultats financiers et une croissance prévue pour 2026

Résultats Financiers Efficacité Opérationnelle Prévisions Pour 2026 Croissance Des Biosimilaires Défis Liés Aux Génériques
BRIEF

published on 02/25/2026 at 07:05, 6 months 14 days ago

Sandoz Reports Strong Financial Results and Forecasted Growth for 2026

Financial Results Operational Efficiencies 2026 Forecast Biosimilars Growth Generics Challenges
PRESS RELEASE

published on 02/25/2026 at 07:00, 6 months 14 days ago

Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz reports strong full-year results for 2025 with net sales growth and core EBITDA margin expansion. The guidance for 2026 anticipates further growth in net sales and core EBITDA margin

Net Sales Growth Full-year Results Sandoz Financial Guidance 2026 Core EBITDA Margin Expansion

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 40 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 15 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 54 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 20 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 40 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 11:35, 5 minutes ago

EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 10 minutes ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 25 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 20 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 35 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 40 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 40 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 40 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 40 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 10 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE